Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patients

January 21, 2015 5:52 PM

8 0

Novartis International AG / Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patients . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Basel, January 21, 2015- Novartis today announced the US Food and Drug Administration (FDA) has approved Cosentyx(TM) (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy (a drug that is absorbed into the bloodstream and dis...

Also read: Johnny Manziel Agrees to Treatment ... In Domestic Violence Case

Read more

To category page

Loading...